JP2022504990A5 - - Google Patents
Info
- Publication number
- JP2022504990A5 JP2022504990A5 JP2021520923A JP2021520923A JP2022504990A5 JP 2022504990 A5 JP2022504990 A5 JP 2022504990A5 JP 2021520923 A JP2021520923 A JP 2021520923A JP 2021520923 A JP2021520923 A JP 2021520923A JP 2022504990 A5 JP2022504990 A5 JP 2022504990A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- active substance
- reduces
- pkc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024031893A JP2024063161A (ja) | 2018-10-16 | 2024-03-04 | 血管型エーラース・ダンロス症候群および関連障害を処置するための組成物および方法 |
| JP2025076487A JP2025118759A (ja) | 2018-10-16 | 2025-05-02 | 血管型エーラース・ダンロス症候群および関連障害を処置するための組成物および方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862746524P | 2018-10-16 | 2018-10-16 | |
| US62/746,524 | 2018-10-16 | ||
| US201862747587P | 2018-10-18 | 2018-10-18 | |
| US62/747,587 | 2018-10-18 | ||
| US201962838049P | 2019-04-24 | 2019-04-24 | |
| US62/838,049 | 2019-04-24 | ||
| PCT/US2019/056616 WO2020081741A2 (en) | 2018-10-16 | 2019-10-16 | Compositions and methods for treating vascular ehlers danlos syndrome and associated disorders |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024031893A Division JP2024063161A (ja) | 2018-10-16 | 2024-03-04 | 血管型エーラース・ダンロス症候群および関連障害を処置するための組成物および方法 |
| JP2025076487A Division JP2025118759A (ja) | 2018-10-16 | 2025-05-02 | 血管型エーラース・ダンロス症候群および関連障害を処置するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022504990A JP2022504990A (ja) | 2022-01-13 |
| JP2022504990A5 true JP2022504990A5 (enExample) | 2022-09-20 |
| JP7678748B2 JP7678748B2 (ja) | 2025-05-16 |
Family
ID=70284358
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021520923A Active JP7678748B2 (ja) | 2018-10-16 | 2019-10-16 | 血管型エーラース・ダンロス症候群および関連障害を処置するための組成物および方法 |
| JP2024031893A Pending JP2024063161A (ja) | 2018-10-16 | 2024-03-04 | 血管型エーラース・ダンロス症候群および関連障害を処置するための組成物および方法 |
| JP2025076487A Pending JP2025118759A (ja) | 2018-10-16 | 2025-05-02 | 血管型エーラース・ダンロス症候群および関連障害を処置するための組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024031893A Pending JP2024063161A (ja) | 2018-10-16 | 2024-03-04 | 血管型エーラース・ダンロス症候群および関連障害を処置するための組成物および方法 |
| JP2025076487A Pending JP2025118759A (ja) | 2018-10-16 | 2025-05-02 | 血管型エーラース・ダンロス症候群および関連障害を処置するための組成物および方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11938135B2 (enExample) |
| EP (2) | EP4268822A3 (enExample) |
| JP (3) | JP7678748B2 (enExample) |
| KR (1) | KR20210094532A (enExample) |
| CN (2) | CN121197400A (enExample) |
| AU (2) | AU2019359872B2 (enExample) |
| BR (1) | BR112021007237A2 (enExample) |
| CA (1) | CA3116321A1 (enExample) |
| DK (1) | DK3866799T3 (enExample) |
| ES (1) | ES2973130T3 (enExample) |
| FI (1) | FI3866799T3 (enExample) |
| IL (1) | IL281623A (enExample) |
| MX (1) | MX2021004387A (enExample) |
| PL (1) | PL3866799T3 (enExample) |
| PT (1) | PT3866799T (enExample) |
| WO (1) | WO2020081741A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121197400A (zh) | 2018-10-16 | 2025-12-26 | 约翰斯·霍普金斯大学 | 用于治疗血管性埃勒斯-当洛斯综合征和有关障碍的组合物和方法 |
| WO2021202643A1 (en) * | 2020-03-31 | 2021-10-07 | The Regents Of The University Of California | Compositions and methods for treating dysregulated wound healing |
| EP4208203A4 (en) * | 2020-09-04 | 2024-09-04 | The Johns Hopkins University | TREATMENT OF VASCULAR EHLERS-DANLOS SYNDROME AND ASSOCIATED SYNDROMES |
| WO2023150702A2 (en) * | 2022-02-03 | 2023-08-10 | The Johns Hopkins University | Compositions and methods for treatment of connective tissue disorders |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| DE102004019413A1 (de) | 2004-04-19 | 2005-11-24 | Phenos Gmbh | Hemmung der Proteinkinase C epsilon zur Behandlung von Krankheiten |
| WO2013170147A1 (en) * | 2012-05-11 | 2013-11-14 | Yale University | Compounds useful for promoting protein degradation and methods using same |
| AU2016232705C1 (en) * | 2015-03-18 | 2021-06-17 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
| BR112018008882A8 (pt) | 2015-11-03 | 2019-02-26 | Univ Texas | método para tratar um distúrbio proliferativo e produto farmacêutico |
| WO2018160987A1 (en) | 2017-03-02 | 2018-09-07 | The Johns Hopkins University | Map kinase pathway targets for the treatment of marfan syndrome |
| CN121197400A (zh) | 2018-10-16 | 2025-12-26 | 约翰斯·霍普金斯大学 | 用于治疗血管性埃勒斯-当洛斯综合征和有关障碍的组合物和方法 |
-
2019
- 2019-10-16 CN CN202511337632.1A patent/CN121197400A/zh active Pending
- 2019-10-16 DK DK19872573.1T patent/DK3866799T3/da active
- 2019-10-16 BR BR112021007237-3A patent/BR112021007237A2/pt not_active Application Discontinuation
- 2019-10-16 EP EP23191111.6A patent/EP4268822A3/en active Pending
- 2019-10-16 CA CA3116321A patent/CA3116321A1/en active Pending
- 2019-10-16 EP EP19872573.1A patent/EP3866799B1/en active Active
- 2019-10-16 CN CN201980067015.0A patent/CN113194946B/zh active Active
- 2019-10-16 PT PT198725731T patent/PT3866799T/pt unknown
- 2019-10-16 MX MX2021004387A patent/MX2021004387A/es unknown
- 2019-10-16 US US17/286,414 patent/US11938135B2/en active Active
- 2019-10-16 FI FIEP19872573.1T patent/FI3866799T3/fi active
- 2019-10-16 KR KR1020217014599A patent/KR20210094532A/ko active Pending
- 2019-10-16 ES ES19872573T patent/ES2973130T3/es active Active
- 2019-10-16 PL PL19872573.1T patent/PL3866799T3/pl unknown
- 2019-10-16 JP JP2021520923A patent/JP7678748B2/ja active Active
- 2019-10-16 WO PCT/US2019/056616 patent/WO2020081741A2/en not_active Ceased
- 2019-10-16 AU AU2019359872A patent/AU2019359872B2/en active Active
-
2021
- 2021-03-18 IL IL281623A patent/IL281623A/en unknown
-
2024
- 2024-02-07 US US18/435,769 patent/US20240408091A1/en active Pending
- 2024-03-04 JP JP2024031893A patent/JP2024063161A/ja active Pending
-
2025
- 2025-01-16 AU AU2025200315A patent/AU2025200315A1/en active Pending
- 2025-05-02 JP JP2025076487A patent/JP2025118759A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hussong et al. | Soluble pathogenic tau enters brain vascular endothelial cells and drives cellular senescence and brain microvascular dysfunction in a mouse model of tauopathy | |
| Sahin et al. | The cell survival kinase SGK 1 and its targets FOXO 3a and NDRG 1 in aged human brain | |
| Yang et al. | Sildenafil potentiates bone morphogenetic protein signaling in pulmonary arterial smooth muscle cells and in experimental pulmonary hypertension | |
| Ephstein et al. | Critical role of S1PR1 and integrin β4 in HGF/c-Met-mediated increases in vascular integrity | |
| US10143703B2 (en) | Treating ocular neovascularization | |
| CN104244956A (zh) | 使用环糊精的方法 | |
| Bell-Temin et al. | Quantitative proteomic characterization of ethanol-responsive pathways in rat microglial cells | |
| Gao et al. | Reticulon 4B (Nogo‐B) facilitates hepatocyte proliferation and liver regeneration in mice | |
| Peng et al. | Spinal serum-inducible and glucocorticoid-inducible kinase 1 mediates neuropathic pain via kalirin and downstream PSD-95-dependent NR2B phosphorylation in rats | |
| Zhang et al. | Adaptive responses of TRPC1 and TRPC3 during skeletal muscle atrophy and regrowth | |
| Schwedler et al. | Native C-reactive protein induces endothelial dysfunction in ApoE−/− mice: implications for iNOS and reactive oxygen species | |
| Marmorato et al. | Involvement of the annexin A1-Fpr anti-inflammatory system in the ocular allergy | |
| Shi et al. | The impact of simulated weightlessness on endothelium-dependent angiogenesis and the role of caveolae/caveolin-1 | |
| Peitzman et al. | Agonist binding to β-adrenergic receptors on human airway epithelial cells inhibits migration and wound repair | |
| JP2025160344A (ja) | 加齢性黄斑変性を処置するための方法および組成物 | |
| Lok et al. | Neuronal low-density lipoprotein receptor-related protein 1 (LRP1) enhances the anti-apoptotic effect of intravenous immunoglobulin (IVIg) in ischemic stroke | |
| Vaajanen et al. | Angiotensin receptors in the eyes of arterial hypertensive rats | |
| Shao et al. | Vitreous and serum levels of transthyretin (TTR) in high myopia patients are correlated with ocular pathologies | |
| Dopp et al. | Influence of Intermittent Hypoxia on Myocardial and Hepatic P‐glycoprotein Expression in a Rodent Model | |
| JP6709493B2 (ja) | 進行性骨化性線維異形成症治療剤 | |
| JP2023521071A (ja) | Ｔｒｋ－Ｂに基づく治療剤、医薬組成物、及び関連するバイオマーカー | |
| WO2018231025A9 (ko) | 면역세포 이동에 의한 질환의 치료제 및 이의 스크리닝 방법 | |
| WO2011109650A1 (en) | Method of treating acute lung injury using sphingosine 1 phosphate analoges or sphingosine 1 phosphate receptor agonists | |
| US20210380722A1 (en) | Compositions and methods for the treatment of major depressive disorder | |
| US20220401428A1 (en) | Method for Treatment of Alzheimer's Disease |